Darbepoetin alfa has [[Boxed warning|black box warnings]] in the United States for increased risk of [[death]], [[myocardial infarction]], [[stroke]], [[venous thromboembolism]], [[thrombosis]] of vascular access, and [[tumor]] progression or recurrence. To avoid side effects, it is recommended for patients with chronic renal failure or cancer to use the lowest possible dose needed to avoid red blood cell (RBC) [[Blood transfusion|transfusions]].<ref name=PI>{{cite web|title=Prescribing Information: Aranesp Â® (darbepoetin alfa) injection, for intravenous or subcutaneous use|url=http://pi.amgen.com/united_states/aranesp/ckd/aranesp_pi_hcp_english.pdf|publisher=Amgen Inc. Thousand Oaks, CA|accessdate=3 November 2014}}</ref>

 


 
In addition to those listed in the black box warning, use of darbepoetin alfa also increases the risk of cardiovascular problems, including [[cardiac arrest]], arrhythmia, [[hypertension]] and  [[congestive heart failure]], and [[edema]].<ref name="Lexi"/> A recent study has extended these findings to treatment of patients exhibiting cancer-related anemia (distinct from anemia resulting from chemotherapy).<ref>{{cite news |first=Andrew |last=Pollack

 
| title=Amgen Finds Anemia Drug Holds Risks in Cancer Use

 
| url=https://www.nytimes.com/2007/01/26/business/26amgen.html?th&emc=th

 
| publisher=The New York Times |date=2007-01-26 |accessdate=2007-01-27 }}</ref>{{mcn|date=February 2015}} Other reported adverse reactions include increased risk of [[seizure]], [[hypotension]], and chest pain.

 

